{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.1444.3.214",
  "meta" : {
    "versionId" : "11",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail" : {
        "name" : "American Society of Clinical Oncology Author"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-07-03"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2023-04-11"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.214",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.1444.3.214"
    }
  ],
  "version" : "20230411",
  "name" : "BRAFV600Testing",
  "title" : "BRAF V600 Testing",
  "status" : "active",
  "date" : "2023-04-11T01:00:57-04:00",
  "publisher" : "American Society of Clinical Oncology Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts for the procedure of BRAF V600 testing.),(Data Element Scope: This value set may use a model element related to Procedure.),(Inclusion Criteria: Includes concepts that represent a procedure for BRAF V600 testing.),(Exclusion Criteria: No exclusions.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "concept" : [
          {
            "code" : "81210",
            "display" : "BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)"
          },
          {
            "code" : "81455",
            "display" : "Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis"
          },
          {
            "code" : "81479",
            "display" : "Unlisted molecular pathology procedure"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:c0a60b5c-d590-445d-9c1e-3ddd8018fd29",
    "timestamp" : "2025-05-23T21:55:00-04:00",
    "total" : 3,
    "contains" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "81210",
        "display" : "BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "81455",
        "display" : "Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "81479",
        "display" : "Unlisted molecular pathology procedure"
      }
    ]
  }
}
